Literature DB >> 8892734

Fanconi's anemia and malignancies.

B P Alter1.   

Abstract

Patients with Fanconi's anemia (FA) are at a high risk for development of malignancies. It is well-known that leukemia occurs in approximately 10% of cases, with increasing risk with age. Less commonly recognized is the risk for myelodysplastic syndromes (approximately 5%); the relationship between myelodysplasia and evolution to leukemia remains speculative. What also needs to be emphasized is that older patients have an ever-increasing risk for development of solid tumors, with at least 5% reported to have liver tumors (male:female ratio, 2:1) and an equal number of other cancers (female:male ratio, 3:1, even after exclusion of gynecologic malignancies). Hematologists have tended to focus on aplastic anemia and leukemia. As FA patients live longer, more of the other malignancies will occur, perhaps related to cord blood or bone marrow transplant, or treatment with cytokines. This review identifies the types of tumors for which patients with Fanconi's anemia are at risk.

Entities:  

Mesh:

Year:  1996        PMID: 8892734     DOI: 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  46 in total

1.  GS-nitroxide (JP4-039)-mediated radioprotection of human Fanconi anemia cell lines.

Authors:  Mark E Bernard; Hyun Kim; Hebist Berhane; Michael W Epperly; Darcy Franicola; Xichen Zhang; Frank Houghton; Donna Shields; Hong Wang; Christopher J Bakkenist; Marie-Celine Frantz; Erin M Forbeck; Julie P Goff; Peter Wipf; Joel S Greenberger
Journal:  Radiat Res       Date:  2011-09-22       Impact factor: 2.841

Review 2.  Fanconi anaemia.

Authors:  M D Tischkowitz; S V Hodgson
Journal:  J Med Genet       Date:  2003-01       Impact factor: 6.318

Review 3.  The role of DNA exonucleases in protecting genome stability and their impact on ageing.

Authors:  Penelope A Mason; Lynne S Cox
Journal:  Age (Dordr)       Date:  2011-09-23

4.  Continuous in vivo infusion of interferon-gamma (IFN-gamma) enhances engraftment of syngeneic wild-type cells in Fanca-/- and Fancg-/- mice.

Authors:  Yue Si; Samantha Ciccone; Feng-Chun Yang; Jin Yuan; Daisy Zeng; Shi Chen; Henri J van de Vrugt; John Critser; Fre Arwert; Laura S Haneline; D Wade Clapp
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

Review 5.  Topics in pediatric leukemia--Fanconi's anemia: new insights.

Authors:  Noah Federman; Kathleen M Sakamoto
Journal:  MedGenMed       Date:  2005-04-06

6.  Fanconi's anemia in monozygotic twins.

Authors:  Fulton D'Souza; M K Usha; S D Subba Rao
Journal:  Indian J Pediatr       Date:  2007-09       Impact factor: 1.967

7.  Radiologic differences between bone marrow stromal and hematopoietic progenitor cell lines from Fanconi Anemia (Fancd2(-/-)) mice.

Authors:  Hebist Berhane; Michael W Epperly; Julie Goff; Ronny Kalash; Shaonan Cao; Darcy Franicola; Xichen Zhang; Donna Shields; Frank Houghton; Hong Wang; Peter Wipf; Kalindi Parmar; Joel S Greenberger
Journal:  Radiat Res       Date:  2014-01-07       Impact factor: 2.841

8.  Amelioration of radiation-induced oral cavity mucositis and distant bone marrow suppression in fanconi anemia Fancd2-/- (FVB/N) mice by intraoral GS-nitroxide JP4-039.

Authors:  Hebist Berhane; Ashwin Shinde; Ronny Kalash; Karen Xu; Michael W Epperly; Julie Goff; Darcy Franicola; Xichen Zhang; Tracy Dixon; Donna Shields; Hong Wang; Peter Wipf; Song Li; Xiang Gao; Joel S Greenberger
Journal:  Radiat Res       Date:  2014-06-16       Impact factor: 2.841

9.  Nuclear Pedigree Criteria for the Identification of Individuals Suspected to be at Risk of an Inherited Predisposition to Renal Cancer.

Authors:  Aleksandra Tołoczko-Grabarek; Andrzej Sikorski; Marek Brzosko; Jan Lubiński
Journal:  Hered Cancer Clin Pract       Date:  2005-08-15       Impact factor: 2.857

Review 10.  The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma.

Authors:  Lindsey E Romick-Rosendale; Vivian W Y Lui; Jennifer R Grandis; Susanne I Wells
Journal:  Mutat Res       Date:  2013-01-17       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.